DiaMedica Therapeutics Inc.

3.33+0.0100+0.30%Vol 136.75K1Y Perf -47.27%
Jul 27th, 2021 14:06 DELAYED
BID3.33 ASK3.34
Open3.35 Previous Close3.32
Pre-Market- After-Market-
 - -%  - -
Target Price
21.50 
Analyst Rating
Strong Buy 1.50
Potential %
555.49 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/100 
Growth Ranking
★★★★★     68.51
Insiders Shares Cnt. % 3/6/12 mo.
-/-/100 
Income Ranking
 —    -
Market Cap62.56M 
Earnings Rating
Buy
Price Range Ratio 52W %
2.08 
Earnings Date
10th Aug 2021

Today's Price Range

3.173.37

52W Range

3.1710.88

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-15.52%
1 Month
-54.58%
3 Months
-65.31%
6 Months
-58.76%
1 Year
-47.27%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
DMAC3.330.01000.30
AAPL146.13-2.8600-1.92
GOOG2 706.45-86.4400-3.10
MSFT284.07-4.9800-1.72
XOM57.55-0.9300-1.59
WFC45.040.03000.07
JNJ172.280.41000.24
FB365.89-6.5700-1.76
GE13.060.14001.08
JPM151.60-0.0500-0.03
Earnings HistoryEstimateReportedSurprise %
Q01 2021-0.23-0.1917.39
Q04 2020-0.18-0.23-27.78
Q03 2020--0.19-
Q02 2020--0.17-
Q01 2020-0.28-0.1932.14
Q04 2019-0.25-0.2116.00
Q03 2019-0.19-0.20-5.26
Q02 2019-0.28-0.2125.00
Earnings Per EndEstimateRevision %Trend
6/2021 QR-0.195.00Positive
9/2021 QR-0.22-4.76Negative
12/2021 FY-0.833.49Positive
12/2022 FY-0.0993.62Positive
Next Report Date10th Aug 2021
Estimated EPS Next Report-0.19
Estimates Count2
EPS Growth Next 5 Years %30.00
Volume Overview
Volume136.75K
Shares Outstanding18.79M
Trades Count1.01K
Dollar Volume1.34M
Avg. Volume202.00K
Avg. Weekly Volume194.32K
Avg. Monthly Volume651.69K
Avg. Quarterly Volume283.45K

DiaMedica Therapeutics Inc. (NASDAQ: DMAC) stock closed at 3.32 per share at the end of the most recent trading day (a -10.03% change compared to the prior day closing price) with a volume of 322.75K shares and market capitalization of 62.56M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 9 people. DiaMedica Therapeutics Inc. CEO is Rick Pauls.

The one-year performance of DiaMedica Therapeutics Inc. stock is -47.27%, while year-to-date (YTD) performance is -67.26%. DMAC stock has a five-year performance of %. Its 52-week range is between 3.17 and 10.88, which gives DMAC stock a 52-week price range ratio of 2.08%

DiaMedica Therapeutics Inc. currently has a PE ratio of -, a price-to-book (PB) ratio of 6.03, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -68.06%, a ROC of -73.44% and a ROE of -72.29%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from DiaMedica Therapeutics Inc., there were 1 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.19 for the next earnings report. DiaMedica Therapeutics Inc.’s next earnings report date is 10th Aug 2021.

The consensus rating of Wall Street analysts for DiaMedica Therapeutics Inc. is Strong Buy (1.5), with a target price of $21.5, which is +555.49% compared to the current price. The earnings rating for DiaMedica Therapeutics Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

DiaMedica Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

DiaMedica Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 15.68, ATR14 : 0.40, CCI20 : -116.45, Chaikin Money Flow : -0.34, MACD : -0.83, Money Flow Index : 61.12, ROC : -19.61, RSI : 23.19, STOCH (14,3) : 2.11, STOCH RSI : 0.00, UO : 37.84, Williams %R : -97.89), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of DiaMedica Therapeutics Inc. in the last 12-months were: Randall Michael Giuffre (Buy at a value of $63 912), Richard D. Pilnik (Buy at a value of $26 200), Scott Kellen (Buy at a value of $8 387)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (50.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Buy
1 (50.00 %)
1 (100.00 %)
1 (100.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.50
Moderate Buy
2.00
Moderate Buy
2.00

DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. It is principally engaged in the business activity of developing treatments for unmet clinical need or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.

CEO: Rick Pauls

Telephone: +1 763 496-5454

Address: Two Carlson Parkway, Minneapolis 55447, MN, US

Number of employees: 9

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

55%45%

Bearish Bullish

59%41%

Bearish Bullish

50%50%

News

Stocktwits